Serum Golgi Phosphoprotein 2 level: A better marker than alpha‐fetoprotein for diagnosing early hepatocellular carcinoma
Xiaohua Li, Kaichun Wu, Daiming Fan – 23 June 2009
CCR2 promotes hepatic fibrosis in mice
Ekihiro Seki, Samuele de Minicis, Sayaka Inokuchi, Kojiro Taura, Katsumi Miyai, Nico van Rooijen, Robert F. Schwabe, David A. Brenner – 23 June 2009 – Chemokines and chemokine receptors contribute to the migration of hepatic stellate cells (HSCs) and Kupffer cells, two key cell types in fibrogenesis. Here, we investigate the role of CCR2, the receptor for monocyte chemoattractant protein (MCP)‐1, MCP‐2, and MCP‐3, in hepatic fibrosis. Hepatic CCR2, MCP‐1, MCP‐2, and MCP‐3 messenger RNA expression was increased after bile duct ligation (BDL).
Orlistat for overweight subjects with nonalcoholic steatohepatitis
Teoman Dogru, Cemal Nuri Ercin, Ilker Tasci, Serkan Tapan, Zeki Yesilova, Ahmet Uygun – 28 May 2009
Intramitochondrial crystalline inclusions in nonalcoholic steatohepatitis
Stephen H. Caldwell, Luiz Antonio R. de Freitas, Sang H. Park, Maria Lucia V. Moreno, Jan A. Redick, Christine A. Davis, Barbee J. Sisson, James T. Patrie, Helma Cotrim, Curtis K. Argo, Abdullah Al‐Osaimi – 28 May 2009 – Mitochondrial dysfunction is an important element in the pathogenesis of nonalcoholic steatohepatitis (NASH). Intramitochondrial crystals (IMCs) are a well‐documented morphological abnormality seen on transmission electron microscopy in this disease.
Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2−/− mice
Emina Halilbasic, Romina Fiorotto, Peter Fickert, Hanns‐Ulrich Marschall, Tarek Moustafa, Carlo Spirli, Andrea Fuchsbichler, Judith Gumhold, Dagmar Silbert, Kurt Zatloukal, Cord Langner, Uday Maitra, Helmut Denk, Alan F. Hofmann, Mario Strazzabosco, Michael Trauner – 28 May 2009 – 24‐norursodeoxycholic acid (norUDCA), a side chain–modified ursodeoxycholic acid derivative, has dramatic therapeutic effects in experimental cholestasis and may be a promising agent for the treatment of cholestatic liver diseases.
Living donor liver transplantation using a graft from a donor with situs inversus totalis
Jae Min Chun, Gum O. Jung, Gyu Seong Choi, Jae Berm Park, Choon Hyuck David Kwon, Sung‐Joo Kim, Jae‐Won Joh, Suk‐Koo Lee – 28 May 2009
Use of a donor aortic interposition allograft to treat stenosis of the suprahepatic inferior vena cava after liver transplantation
Kourosh Saeb‐Parsy, Asif Jah, Andrew J. Butler, Stephen Large, Gavin J. Pettigrew, Raaj K. Praseedom, Christopher J. Watson, Neville V. Jamieson – 28 May 2009
Management of adult patients with ascites due to cirrhosis: An update
Bruce A. Runyon – 28 May 2009
Methodological reporting of randomized clinical trials in major gastroenterology and hepatology journals in 2006
Yu Bai, Jun Gao, Duo‐Wu Zou, Zhao‐Shen Li – 28 May 2009 – To determine the current quality of reporting of randomized clinical trials (RCTs) in the field of gastroenterology and hepatology, we evaluated the methodological reporting of RCTs in six major gastroenterology and hepatology journals.